Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 5,821 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) insider Terrie Curran sold 5,821 shares of the company’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $8.20, for a total value of $47,732.20. Following the sale, the insider now directly owns 176,807 shares of the company’s stock, valued at $1,449,817.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phathom Pharmaceuticals Price Performance

Shares of PHAT stock opened at $8.61 on Monday. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.09 and a fifty-two week high of $19.95. The stock’s 50-day moving average is $9.81 and its two-hundred day moving average is $9.77. The firm has a market cap of $358.36 million, a P/E ratio of -1.84 and a beta of 0.29.

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($1.32) earnings per share for the quarter. As a group, research analysts expect that Phathom Pharmaceuticals, Inc. will post -5.22 EPS for the current year.

Analyst Ratings Changes

PHAT has been the topic of several recent analyst reports. Jefferies Financial Group initiated coverage on Phathom Pharmaceuticals in a research report on Thursday, October 20th. They set a “buy” rating and a $16.00 price target on the stock. Needham & Company LLC dropped their price target on Phathom Pharmaceuticals from $38.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, January 4th. Guggenheim dropped their price target on Phathom Pharmaceuticals from $30.00 to $22.00 in a research report on Tuesday, January 10th. Finally, BMO Capital Markets dropped their price target on Phathom Pharmaceuticals from $38.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, January 4th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Phathom Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $21.40.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PHAT. Ensign Peak Advisors Inc increased its position in Phathom Pharmaceuticals by 51.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 1,675,488 shares of the company’s stock worth $14,140,000 after purchasing an additional 570,729 shares during the last quarter. Medicxi Ventures Management Jersey Ltd increased its position in Phathom Pharmaceuticals by 18.5% in the 2nd quarter. Medicxi Ventures Management Jersey Ltd now owns 2,450,679 shares of the company’s stock worth $20,684,000 after purchasing an additional 382,818 shares during the last quarter. 683 Capital Management LLC increased its position in Phathom Pharmaceuticals by 15.6% in the 3rd quarter. 683 Capital Management LLC now owns 1,663,943 shares of the company’s stock worth $18,436,000 after purchasing an additional 223,943 shares during the last quarter. Western Standard LLC bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth about $920,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth about $6,703,000. 98.57% of the stock is owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Company Profile

(Get Rating)

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.